 Artist: Atlanta Rhythm Section: mp3 download Genre(s): Rock Discography:  Eufaula Year: 1999 Tracks: 11  Partly Plugged Year: 1997 Tracks: 10  Truth In A Structured Form Year: 1989 Tracks: 11  Quinella Year: 1981 Tracks: 9  The Boys From Doraville Year: 1980 Tracks: 9  Underdog Year: 1979 Tracks: 8  Are You Ready (Live) Year: 1979 Tracks: 13  Champagne Jam Year: 1978 Tracks: 8  Red Tape Year: 1976 Tracks: 8  A Rock And Roll Alternative Year: 1976 Tracks: 8  Dog Days Year: 1975 Tracks: 8  Third Annual Pipe Dream Year: 1974 Tracks: 10  Atlanta Rhythm Section Year: 1971 Tracks: 7 Often described as a more than radio-friendly variant of Lynyrd Skynyrd or the Allman Brothers, the Atlanta Rhythm Section was one of many Southern rock bands to hit the upper reaches of the charts during the recent '70s. Hailing from the little town of Doraville, Georgia, the beginning of the Atlanta Rhythm Section fanny be traced plump for to 1970. It was then that a local recording studio apartment was opened, Studio One, and the remnants of deuce groups (the Candymen and the Classics Four), became the studio's menage band. One of the facility's oral sex figures, Buddy Buie, before long began aggregation the academic session striation -- vocaliser Rodney Justo, guitarist Barry Bailey, bassist Paul Goddard, keyboardist Dean Daughtry, and drummer Robert Nix. After playing on respective artists' recordings, it was trenchant to take the stria a stone's throw further and peeing the radical of players a material band, leading to the shaping of the Atlanta Rhythm Section. Buie shortly became an unseeable fifth member of the fledgeling band; he served as their director and producer, in addition to providing a major hand in the songwriting department. Finding fourth dimension betwixt roger Sessions to record their possess original material (which was ab initio, only subservient), an early demo lesion up landing the band a record handle. The group's first base few albums failed to generate much chart activeness (1972's Capital of Georgia Rhythm Section, 1973's Back Up Against the Wall, 1974's Third Annual Pipe Dream, 1975's Blackguard Days, and 1976's Red Tape), simply it was during this clip that Justo was replaced with newcomer Ronnie Hammond, which would lastly yield dividends for the group. Although they had gained quite a bit of radio airplay down south, their record company began to place press on the quintette to deliver a single that would go against them across the nation. The involve worked -- the Atlanta Rhythm Section scored a Top Ten unmarried, "So Into You," on their following sack, 1976's A Rock and Roll Alternative, which was the group's first theme record album to reach gold documentation. But this wouldn't be the group's commercial vizor, as they scored the highest charting record album of their vocation in 1978, the Top Ten Bubbly Jam, which spawned 2 hit singles -- "I'm Not Gonna Let It Bother Me Tonight" and "Complex quantity Lover." To maintain up their high profile, the Atlanta Rhythm Section shortly became unrivalled of the hardest touring bands of the total Southern rock musical genre (including a public presentation at the White House for then-president Jimmy Carter). But the group's commercial success would be momentary -- it appeared as shortly as mainstream rock candy fans embraced the Atlanta Rhythm Section, they barely as quickly forgot around them. Each subsequent record album -- 1979's Underdog and lively coiffure Are You Ready, 1980s The Boys from Doraville, and 1981's Quinella -- sold less than the premature one, resulting in the band's split presently thenceforth. In the rouse of their split, the Atlanta Rhythm Section has reunited periodically for tours (although only a few original members would be gift), and issued their first all-new studio album in more than a decennary in 1999, Eufala. Additionally, some of country-rock's biggest names leave bypast on to track record Atlanta Rhythm Section covers -- Travis Tritt, Wynonna Judd, and Charlie Daniels, among others. |
Wednesday 3 September 2008
Download Atlanta Rhythm Section mp3
Sunday 24 August 2008
Cymbalta Receives European Approval For The Treatment Of Generalised Anxiety Disorder
�Eli Lilly and Co (NYSE:
LLY) and Boehringer Ingelheim cause announced that the European Commission
has approved the use of Cymbalta(R) (duloxetine) for the treatment of
Generalised Anxiety Disorder (GAD). This favorable reception -- the fourth for
duloxetine in Europe -- was issued on 28 July next an initial positive
view issued by the European Medicines Agency's (EMEA) Committee for
Medicinal Products for Human Use (CHMP) on 26 June 2008.
The approval is based upon the results of fin clinical studies of GAD
-- quaternary double-blind short-term (acute) placebo-controlled studies and a
placebo-controlled relapse prevention study -- involving more than than 2,000
non-depressed adults with GAD. In each of the quaternary acute placebo-controlled
studies safety and efficacy were assessed. Duloxetine significantly
improved core anxiety symptoms (as calculated by the Hamilton Anxiety Scale)
compared with placebo (p less than or equal to 0.001, p=0.02, p=0.007, p
less than or equal to 0.001 respectively)(1,2,3,4) and patients
demonstrated improvement in role functioning, including ability to perform
everyday activities in lick, home and in social situations.(5,6) In
addition, duloxetine significantly decreased the likelihood of recidivate in
those patients wHO initially responded to duloxetine and were maintained on
treatment for six months compared with those switched to placebo.(7) The
most common side personal effects in these studies included nausea, tiredness, dry
mouth, drowsiness, constipation, insomnia, reduced appetite,
hyperidrosis (excessive diaphoresis), decreased libido, vomiting,
ejaculation delay and erectile disfunction.
Although worldwide prevalence is not currently known, more than than ball club
million Europeans(8,9) and 6 million people in Central and South America
ar estimated to suffer from GAD(10), which is characterised by inordinate
anxiety and worry about a number of events and activities (such as
performance at work or school) all over a sustained period of at least six
months.(11)
This regulatory approval paves the way for launches in Europe and
applies to all 27 countries of the European Union, as well as Norway,
Iceland, and Liechtenstein.
Cymbalta(R), a member of a division of drugs commonly referred to as
serotonin and noradrenaline re-uptake inhibitors,(12) is already approved by
the EMEA to care for major depressive disorder and diabetic peripheral
neuropathic botheration. Duloxetine gained marketing authorization for the
treatment of GAD in Mexico in 2006 and in the United States in 2007.
About Generalised Anxiety Disorder
Approximately nine 1000000 Europeans(8,9) and six meg people in
Central and South America are estimated to suffer from GAD.(10) Quality of
life is affected, as symptoms of GAD bum include exaggerated worry or
chronic anxiety, irritability and poor absorption. Ability to work is
often compromised with the manifestation of physical symptoms such as
muscle stress, fatigue, slumber disturbance and nausea.(11) The illness
tends to be chronic with periods of aggravation and remission. Patients
story that episodes of generalised anxiety disorder are ofttimes brought on,
or worsened, by nerve-wracking life events.(13)
About Duloxetine
While duloxetine's mechanism of action mechanism in humans is non fully known, it
is believed to affect both serotonin- and
ntinence is marketed by Lilly under
the make name Yentreve.(R)
References
(1) Koponen, H., et al. Efficacy of Duloxetine for the Treatment of
Generalized Anxiety Disorder: Implications for Primary Care Physicians.
Prim Care Companion J Clin Psychiatry 2007: 9(2):100-107
(2) Rynn M., et al. Efficacy and Safety of Duloxetine in the Treatment of
Generalized Anxiety Disorder: A Flexible-Dose, Progressive-Titration,
Placebo-Controlled Trial. Depression and Anxiety 2007: 25(3): 182-189.
(3) Hartford, J., et al. Duloxetine as an SNRI Treatment for Generalized
Anxiety Disorder: Results from a Placebo- and Active-Controlled Trial. Int
Clin Psychopharmacol 2007: 22(3):167-74.
(4) Nicolini H, et al. Improvement of psychic and somatic symptoms in
grownup patients with generalized anxiety disorder: Examination from a
duloxetine, venlafaxine extended-release, and placebo-controlled study. In
Press at Psychological Medicine.
(5) Endicott, J., et al. Duloxetine Treatment for Role Functioning
Improvement in Generalized Anxiety Disorder: Three Independent Studies. The
Journal of Clinical Psychiatry 2007: 68(4):518-24
(6) Allgulander, C., et al. Pharmacotherapy of Generalized Anxiety
Disorder: Results of Duloxetine Treatment from a Pooled Analysis of 3
Clinical Trials. Current Medical Research and Opinion 2007: 23(6):
1245-1252
(7) Davidson JRT, et al. Duloxetine treatment for get worse prevention in
adults with generalized anxiety disorder: A 26-week randomised placebo-
controlled study. Poster presented at the American College of
Neuropsychopharmacology annual conference 2007. Boca Raton, Florida
(8) Lieb, R, et al. The epidemiology of generalized anxiety disorder in
Europe. European Neuropsychopharmacology 2005 Aug;15(4):445-52.
(9) National Institute of Economic and Social Research. Summarized from
the National Institute Economic Review,194, 28 October 2005.
(10) Calculated extrapolations of prevalence rates against the
populations of a special country or region, based upon prevalence of
generalised anxiety upset in the US, UK, Canada or Australia. Available
at:
hTTP://www.cureresearch.
LLY) and Boehringer Ingelheim cause announced that the European Commission
has approved the use of Cymbalta(R) (duloxetine) for the treatment of
Generalised Anxiety Disorder (GAD). This favorable reception -- the fourth for
duloxetine in Europe -- was issued on 28 July next an initial positive
view issued by the European Medicines Agency's (EMEA) Committee for
Medicinal Products for Human Use (CHMP) on 26 June 2008.
The approval is based upon the results of fin clinical studies of GAD
-- quaternary double-blind short-term (acute) placebo-controlled studies and a
placebo-controlled relapse prevention study -- involving more than than 2,000
non-depressed adults with GAD. In each of the quaternary acute placebo-controlled
studies safety and efficacy were assessed. Duloxetine significantly
improved core anxiety symptoms (as calculated by the Hamilton Anxiety Scale)
compared with placebo (p less than or equal to 0.001, p=0.02, p=0.007, p
less than or equal to 0.001 respectively)(1,2,3,4) and patients
demonstrated improvement in role functioning, including ability to perform
everyday activities in lick, home and in social situations.(5,6) In
addition, duloxetine significantly decreased the likelihood of recidivate in
those patients wHO initially responded to duloxetine and were maintained on
treatment for six months compared with those switched to placebo.(7) The
most common side personal effects in these studies included nausea, tiredness, dry
mouth, drowsiness, constipation, insomnia, reduced appetite,
hyperidrosis (excessive diaphoresis), decreased libido, vomiting,
ejaculation delay and erectile disfunction.
Although worldwide prevalence is not currently known, more than than ball club
million Europeans(8,9) and 6 million people in Central and South America
ar estimated to suffer from GAD(10), which is characterised by inordinate
anxiety and worry about a number of events and activities (such as
performance at work or school) all over a sustained period of at least six
months.(11)
This regulatory approval paves the way for launches in Europe and
applies to all 27 countries of the European Union, as well as Norway,
Iceland, and Liechtenstein.
Cymbalta(R), a member of a division of drugs commonly referred to as
serotonin and noradrenaline re-uptake inhibitors,(12) is already approved by
the EMEA to care for major depressive disorder and diabetic peripheral
neuropathic botheration. Duloxetine gained marketing authorization for the
treatment of GAD in Mexico in 2006 and in the United States in 2007.
About Generalised Anxiety Disorder
Approximately nine 1000000 Europeans(8,9) and six meg people in
Central and South America are estimated to suffer from GAD.(10) Quality of
life is affected, as symptoms of GAD bum include exaggerated worry or
chronic anxiety, irritability and poor absorption. Ability to work is
often compromised with the manifestation of physical symptoms such as
muscle stress, fatigue, slumber disturbance and nausea.(11) The illness
tends to be chronic with periods of aggravation and remission. Patients
story that episodes of generalised anxiety disorder are ofttimes brought on,
or worsened, by nerve-wracking life events.(13)
About Duloxetine
While duloxetine's mechanism of action mechanism in humans is non fully known, it
is believed to affect both serotonin- and
ntinence is marketed by Lilly under
the make name Yentreve.(R)
References
(1) Koponen, H., et al. Efficacy of Duloxetine for the Treatment of
Generalized Anxiety Disorder: Implications for Primary Care Physicians.
Prim Care Companion J Clin Psychiatry 2007: 9(2):100-107
(2) Rynn M., et al. Efficacy and Safety of Duloxetine in the Treatment of
Generalized Anxiety Disorder: A Flexible-Dose, Progressive-Titration,
Placebo-Controlled Trial. Depression and Anxiety 2007: 25(3): 182-189.
(3) Hartford, J., et al. Duloxetine as an SNRI Treatment for Generalized
Anxiety Disorder: Results from a Placebo- and Active-Controlled Trial. Int
Clin Psychopharmacol 2007: 22(3):167-74.
(4) Nicolini H, et al. Improvement of psychic and somatic symptoms in
grownup patients with generalized anxiety disorder: Examination from a
duloxetine, venlafaxine extended-release, and placebo-controlled study. In
Press at Psychological Medicine.
(5) Endicott, J., et al. Duloxetine Treatment for Role Functioning
Improvement in Generalized Anxiety Disorder: Three Independent Studies. The
Journal of Clinical Psychiatry 2007: 68(4):518-24
(6) Allgulander, C., et al. Pharmacotherapy of Generalized Anxiety
Disorder: Results of Duloxetine Treatment from a Pooled Analysis of 3
Clinical Trials. Current Medical Research and Opinion 2007: 23(6):
1245-1252
(7) Davidson JRT, et al. Duloxetine treatment for get worse prevention in
adults with generalized anxiety disorder: A 26-week randomised placebo-
controlled study. Poster presented at the American College of
Neuropsychopharmacology annual conference 2007. Boca Raton, Florida
(8) Lieb, R, et al. The epidemiology of generalized anxiety disorder in
Europe. European Neuropsychopharmacology 2005 Aug;15(4):445-52.
(9) National Institute of Economic and Social Research. Summarized from
the National Institute Economic Review,194, 28 October 2005.
(10) Calculated extrapolations of prevalence rates against the
populations of a special country or region, based upon prevalence of
generalised anxiety upset in the US, UK, Canada or Australia. Available
at:
hTTP://www.cureresearch.
Wednesday 6 August 2008
Voight Surprised Jolie Became A Mother
Angelina Jolie's dad Jon Voight is amazed his daughter is now a mother of six - because she had no interest in kids when she was younger. The pair late reconciled after a long rift, which started when Voight told a TV interviewer Jolie had "severe emotional problems". And Voight is look forward to meeting his new grandchildren; Knox and Vivienne - Jolie and partner Brad Pitt's one-fifth and
Friday 27 June 2008
Thursday 19 June 2008
Ioan Gruffudd - Gruffudds Bad Audition Lands Rhys A Role
Welsh actor IOAN GRUFFUDD deliberately sabotaged his audition for new movie THE EDGE OF LOVE - in a bid to help his pal MATTHEW RHYS land a part.
Director John Maybury says Rhys is now indebted to Gruffudd after helping him secure a part in the movie based on Welsh poet Dylan Thomas.
Maybury says, "Matthew got his mate Ioan to do a really bad audition on the same tape as his own audition.
"That way I'd look at Ioan's first and say 'Oh, that's bad', before seeing Matthew's wonderful performance."
See Also
Friday 13 June 2008
'Transformers' headed to Blu-ray
Michael Bay gets his way after waiting almost a year
Michael Bay feels vindicated.
Paramount Home Entertainment is releasing his boxoffice hit "Transformers" on Blu-ray Disc, nearly a year after the studio's decision to issue the film in the rival HD DVD format triggered a tirade from the director.
"I've been waiting for 'Transformers' to be released on Blu-ray for a long time, and it was worth the wait," Bay said. He called the Sept. 2 release of the two-disc set "the complete high-definition package for fans."
"It looks stunning and really allows you to engage with this movie in new ways," Bay added. "Remember, I told everyone Blu-ray was best."
He sure did. In August, when Paramount stunned the industry by announcing it was dropping its support for Blu-ray Disc and would release films only in HD DVD, "Transformers" was the flashpoint of the controversy. It was the biggest title Paramount/DreamWorks had in store for the fourth quarter, and a Blu-ray Disc edition had already been mastered and prepped for release.
On his Web site, Bay blasted Paramount's decision to go HD DVD-only and threatened to take his sequel elsewhere.
"I want people to see my movies in the best formats possible," he wrote. "For Paramount to deny people who have Blu-ray sucks! They are progressive by having two formats. No 'Transformers 2' for me."
Bay backtracked, writing the next day that he "overreacted" and "might be back on" for the sequel. As it turns out, HD DVD was soon to be doomed when principal developer Toshiba threw in the towel Feb. 19.
The Blu-ray edition of "Transformers" that Par is preparing will include extensive extras and special features, including a commentary from Bay and two docus about the film's human and robotic stars. Segments include exec producer Steven Spielberg discussing his love for the franchise and a detailed look at the casting process and real-world weapons provided by the military.
"We're so happy to finally bring Michael Bay's true vision to life with this release," Paramount vice chairman Rob Moore said. "Because of Blu-ray's expanded capacity, we are able to elevate the bit rate used for the picture as well as present uncompressed audio in the form of Dolby True HD."
Bay said principal photography on "Transformers 2" is set to begin Monday.
See Also
Friday 6 June 2008
Corrie's Vera speaks about illness
Former 'Coronation Street' actress Liz Dawn has spoken about how her life has changed since she was diagnosed with emphysema five years ago.
The 68-year-old actress told ITV's 'Tonight' that she was told by doctors that she only had one third of her lung capacity left.
Dawn, who played Vera Duckworth in 'Coronation Street', recently quit the show due to ill health.
She said: "I used to go to Granada and I used to go in the dressing room, and I'd be really breathless before I even did anything."
"And I got that bad, at the end that instead of somebody knocking on the door and saying: 'It's your scene', I used to go on a scene earlier and sit on the Duckworths' set."
Dawn also said that she quit smoking after her diagnosis: "When you're addicted to smoking it's very hard to stop... I couldn't answer the phone unless I lit up."
The actress said that she regretted smoking around non-smokers: "I mean there are a lot of non-smokers in 'Coronation Street' that I have stood next to and smoked. Must have been awful mustn't it?"
Dawn's doctor Professor Ashley Woodcock said: "Liz came to me about five years ago really pretty desperate."
"At that point she could walk just a couple of yards... she was in a really bad way."
"Stopping her smoking was really critical and she did that... which has been great because she wouldn't be here now... if she hadn't stopped"
The 68-year-old actress told ITV's 'Tonight' that she was told by doctors that she only had one third of her lung capacity left.
Dawn, who played Vera Duckworth in 'Coronation Street', recently quit the show due to ill health.
She said: "I used to go to Granada and I used to go in the dressing room, and I'd be really breathless before I even did anything."
"And I got that bad, at the end that instead of somebody knocking on the door and saying: 'It's your scene', I used to go on a scene earlier and sit on the Duckworths' set."
Dawn also said that she quit smoking after her diagnosis: "When you're addicted to smoking it's very hard to stop... I couldn't answer the phone unless I lit up."
The actress said that she regretted smoking around non-smokers: "I mean there are a lot of non-smokers in 'Coronation Street' that I have stood next to and smoked. Must have been awful mustn't it?"
Dawn's doctor Professor Ashley Woodcock said: "Liz came to me about five years ago really pretty desperate."
"At that point she could walk just a couple of yards... she was in a really bad way."
"Stopping her smoking was really critical and she did that... which has been great because she wouldn't be here now... if she hadn't stopped"
Subscribe to:
Posts (Atom)